A Pilot Study Of Pembrolizumab And Lenvatinib Combination Therapy In Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Posted Date: Oct 19, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to study the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and lenvatinib may kill more tumor cells. The study will consist of 1 experimental arm where patients will receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, and treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Efficacy will be determined by the overall response rate.
Criteria:
Has A Documented, Previously Treated, Advanced (Unresectable And/Or Metastatic) Gastroesophageal Adenocarcinoma That Is Incurable And For Which Prior First-Line Or Later-Line Standard Of Care (Soc) Treatments Have Failed. Has Measurable Disease Based On R
Keywords:
Adenocarcinoma, Cancer, Head And Neck
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com